Immune Deficiency
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
CSL BehringIL - Bradley
1 program1
Salmonella typhi polysaccharide vaccinePhase 1Vaccine1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Qu BiologicsQBKPN SSI
CSL BehringSalmonella typhi polysaccharide vaccine
Clinical Trials (2)
Total enrollment: 37 patients across 2 trials
Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults
Start: Apr 2023Est. completion: Feb 2026
Phase 2Recruiting
Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency
Start: Jul 2019Est. completion: Dec 202337 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 37 patients
Vaccine is the dominant modality (100% of programs)
2 companies competing in this space